



Figure S1 Encorafenib and cetuximab dual combination has no synergistic impact on PDC viability. BRAF V600E-mutant CRC PDCs were treated with indicated drugs for 24 h. Then, the number of viable cells was determined using a CellTiter 96 AQueous One Solution Cell Proliferation Assay (MTS) and viability was calculated as a percent of the untreated control. No statistical differences were uncovered between the experimental groups when tested using ANOVA with Tukey-adjusted post hoc tests for multiple comparisons. PDC, patient-derived cell; CRC, colorectal cancer; ANOVA, analysis of variance.